OBJECTIVES: The aim of this study was to verify whether intracystic injections of alpha-Interferon (IFN-alpha) in cystic craniopharyngiomas were able to reduce the tumor by activating the Fas apoptotic pathway. MATERIALS AND METHODS: Twenty-one patients with cystic craniopharyngiomas treated at the Pediatric Oncology Institute (IOP/GRAACC) of Federal University of São Paulo were submitted to intracystic chemotherapy with IFN-alpha. The tumor sizes of all patients were monitored and the apoptotic factor soluble FasL (sFasL) concentration was determined by ELISA (enzyme-linked immunosorbent assay) in tumor fluid samples from eight patients. RESULTS: There was a complete reduction in 11 patients, a partial response in seven, and a minor response in three patients. The concentration of sFasL was increased in all the eight patients examined concomitantly with the tumor size reduction. CONCLUSIONS: Our data demonstrated that the IFN-alpha was able to induce Fas-mediated apoptosis together with a reduction in the tumor size; such an observation may suggest the importance to investigate still unexplored mechanisms to be exploited in craniopharyngioma therapy.
OBJECTIVES: The aim of this study was to verify whether intracystic injections of alpha-Interferon (IFN-alpha) in cystic craniopharyngiomas were able to reduce the tumor by activating the Fas apoptotic pathway. MATERIALS AND METHODS: Twenty-one patients with cystic craniopharyngiomas treated at the Pediatric Oncology Institute (IOP/GRAACC) of Federal University of São Paulo were submitted to intracystic chemotherapy with IFN-alpha. The tumor sizes of all patients were monitored and the apoptotic factor soluble FasL (sFasL) concentration was determined by ELISA (enzyme-linked immunosorbent assay) in tumor fluid samples from eight patients. RESULTS: There was a complete reduction in 11 patients, a partial response in seven, and a minor response in three patients. The concentration of sFasL was increased in all the eight patients examined concomitantly with the tumor size reduction. CONCLUSIONS: Our data demonstrated that the IFN-alpha was able to induce Fas-mediated apoptosis together with a reduction in the tumor size; such an observation may suggest the importance to investigate still unexplored mechanisms to be exploited in craniopharyngioma therapy.
Authors: R I Jakacki; B H Cohen; C Jamison; V P Mathews; E Arenson; D C Longee; J Hilden; A Cornelius; M Needle; D Heilman; J C Boaz; T G Luerssen Journal: J Neurosurg Date: 2000-02 Impact factor: 5.115
Authors: Philipp Kickingereder; Mohammad Maarouf; Faycal El Majdoub; Manuel Fuetsch; Ralph Lehrke; Jochen Wirths; Klaus Luyken; Klaus Schomaecker; Harald Treuer; Juergen Voges; Volker Sturm Journal: J Neurooncol Date: 2012-06-21 Impact factor: 4.130
Authors: Stewart Goldman; Ian F Pollack; Regina I Jakacki; Catherine A Billups; Tina Y Poussaint; Adekunle M Adesina; Ashok Panigrahy; Donald W Parsons; Alberto Broniscer; Giles W Robinson; Nathan J Robison; Sonia Partap; Lindsay B Kilburn; Arzu Onar-Thomas; Ira J Dunkel; Maryam Fouladi Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: John-Paul Kilday; Massimo Caldarelli; Luca Massimi; Robert Hsin-Hung Chen; Yi Yen Lee; Muh-Lii Liang; Jeanette Parkes; Thuran Naiker; Marie-Lise van Veelen; Erna Michiels; Conor Mallucci; Benedetta Pettorini; Lisethe Meijer; Christian Dorfer; Thomas Czech; Manuel Diezi; Antoinette Y N Schouten-van Meeteren; Stefan Holm; Bengt Gustavsson; Martin Benesch; Hermann L Müller; Anika Hoffmann; Stefan Rutkowski; Joerg Flitsch; Gabriele Escherich; Michael Grotzer; Helen A Spoudeas; Kristian Azquikina; Michael Capra; Rolando Jiménez-Guerra; Patrick MacDonald; Donna L Johnston; Rina Dvir; Shlomi Constantini; Meng-Fai Kuo; Shih-Hung Yang; Ute Bartels Journal: Neuro Oncol Date: 2017-10-01 Impact factor: 12.300